ANGPTL3 (angiopoietin-like protein 3) is a hepatically-expressed inhibitor of lipoprotein and endothelial lipases that regulates triglyceride-rich lipoprotein metabolism 1. The protein functions by inhibiting lipoprotein lipase (LPL) activity, thereby controlling fatty acid release from circulating triglycerides and modulating fat partitioning between tissues 2. ANGPTL3 regulates multiple lipid pathways including triglyceride homeostasis, cholesterol metabolism, and chylomicron remodeling [UniProt]. Loss-of-function variants in ANGPTL3 reduce plasma triglycerides, LDL cholesterol, and HDL cholesterol, with heterozygous carriers showing significantly reduced coronary artery disease risk (adjusted odds ratio 0.59) 3. Mutations in ANGPTL3 cause familial hypobetalipoproteinemia type 2, a rare genetic disorder characterized by severely reduced lipoprotein levels 4. Therapeutically, ANGPTL3 inhibition via small interfering RNA (solbinsiran) and antisense oligonucleotides reduces triglycerides up to 73%, LDL cholesterol up to 42%, and atherogenic lipoprotein particles in patients with dyslipidemia and familial chylomicronemia syndrome 15. These effects address residual cardiovascular risk associated with triglyceride-rich lipoproteins and remnant cholesterol 6.